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Abstract
Dengue virus (DENV) infection causes dengue fever, dengue hemorrhagic fever and dengue
shock syndrome. It is estimated that a third of the world’s population is at risk for infection,
with an estimated 390 million infections annually. Dengue virus serotype 2 (DENV2) causes
severe epidemics, and the leading tetravalent dengue vaccine has lower efficacy against
DENV2 compared to the other 3 serotypes. In natural DENV2 infections, strongly neutralizing
type-specific antibodies provide protection against subsequent DENV2 infection. While the
epitopes of some human DENV2 type-specific antibodies have been mapped, it is not known
if these are representative of the polyclonal antibody response. Using structure-guided immu-
nogen design and reverse genetics, we generated a panel of recombinant viruses containing
amino acid alterations and epitope transplants between different serotypes. Using this panel
of recombinant viruses in binding, competition, and neutralization assays, we have finely
mapped the epitopes of three human DENV2 type-specific monoclonal antibodies, finding
shared and distinct epitope regions. Additionally, we used these recombinant viruses and
polyclonal sera to dissect the epitope-specific responses following primary DENV2 natural
infection and monovalent vaccination. Our results demonstrate that antibodies raised follow-
ing DENV2 infection or vaccination circulate as separate populations that neutralize by occu-
pying domain III and domain I quaternary epitopes. The fraction of neutralizing antibodies
directed to different epitopes differs between individuals. The identification of these epitopes
could potentially be harnessed to evaluate epitope-specific antibody responses as correlates
of protective immunity, potentially improving vaccine design.
Author summary
Dengue viruses (DENV) are flaviviruses transmitted by mosquitos. There are approxi-
mately 390 million DENV infections every year, making dengue virus a major global
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public health concern. While there is a recently licensed DENV vaccine, it has low efficacy
against preventing DENV2 infections. Individuals that are naturally infected with DENV2
generate neutralizing antibodies that can be protective against reinfection with DENV2.
By studying three of these neutralizing antibodies, we found that they bind to two differ-
ent locations on the surface of the virus. Additionally we found that most individuals that
were naturally infected with DENV2, have antibodies circulating in their blood that target
both of these regions. People who were vaccinated against DENV2 also make antibodies
targeting both of these sites, suggesting they might also be protected against DENV2 infec-
tion. These studies reveal that human antibodies against DENV2 target the same two
regions across multiple individuals. Additionally, for a DENV2 vaccine to be protective, it
may be important to elicit antibodies directed to these regions as well.
Introduction
Dengue virus (DENV) is a single stranded positive sense RNA virus that is transmitted by the
Aedes mosquito [1]. There are four distinct DENV serotypes (DENV1-4), and infection results
in a range of symptoms, from fever and rash to the more serious dengue hemorrhagic fever
and dengue shock syndrome. Over a third of the world’s population is at risk for infection, and
there are an estimated 390 million infections yearly [1]. A primary infection with DENV
results in the induction of serotype cross-neutralizing antibodies which can provide temporary
serotype cross-protective immunity that is not maintained [2]. Over the course of the follow-
ing year, these cross-reactive neutralizing antibodies wane, leaving individuals susceptible to
infection by the remaining three heterologous serotypes [3]. Serotype-specific neutralizing
antibodies are maintained in circulation for decades following exposure and may play a critical
role in providing subsequent protection against the infecting serotype [2,4,5]. While antibodies
are known to play a key role in protection against DENV reinfection [6], it has also been
shown that CD8+ T-cells [7,8], CD4+ T-cells [9], and other mechanisms of cellular immunity
are important for protection [10,11].
The leading DENV vaccines are tetravalent formulations, designed to elicit independent,
hopefully protective, neutralizing antibodies against all four serotypes simultaneously [12].
Phase 3 efficacy trials in Asia and Latin America showed that the recently licensed tetravalent
vaccine, Dengvaxia, had variable efficacy depending on immune status prior to vaccination
and the serotype of infection [13,14]. In mixed populations of susceptibles and DENV-
immunes, Dengvaxia was 50–80% efficacious against DENV1, DENV3 and DENV4, but only
35–42% against DENV2 [13,14]. Vaccine efficacy was significantly lower in those persons sero-
negative to DENV compared to individuals who were DENV seropositive at the time of vacci-
nation [13,14]. Moreover, younger vaccinated individuals were hospitalized for DENV more
frequently than their unvaccinated counterparts, suggesting that poor immunogenicity in
naïve subjects might place individuals at a greater risk of developing severe disease as antibody
levels decline over time [15–18]. Indeed, based on long-term follow up data, Dengvaxia is no
longer recommended for use in DENV-naive individuals [17]. The Dengvaxia clinical trials
have revealed that even individuals with detectable neutralizing antibodies to a particular sero-
type experienced vaccine break-through infections indicating the mere presence of antibodies
that neutralize infection in cell culture assays is not sufficient for protection [19]. Therefore, in
addition to the level of neutralizing antibodies to each serotype, it is critical to define other
properties of human antibodies potentially responsible for durable, protective immunity.
Importantly, while Dengvaxia contains the structural proteins from DENV, the non-structural
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proteins are from yellow fever virus. It is therefore possible that sufficient T-cell immunity
towards DENV epitopes was not achieved [16,20]. DENV vaccines that contain DENV non-
structural proteins might generate a more robust T-cell response, and therefore more closely
resemble a natural DENV infection, which results in a protective immune response [21].
The DENV envelope glycoprotein (E) ectodomain, which is comprised of three domains
(EDI, EDII and EDIII) is the major target of neutralizing antibodies [22]. Two E monomers
form a dimer in a head-to-tail arrangement, three dimers form a raft, and thirty rafts (180
monomers) cover the entire surface of the virus [23]. Our group has previously characterized
components of the antibody response to DENV1, DENV2, DENV3 and DENV4 infection by
mapping the epitopes of strongly neutralizing human monoclonal antibodies (hMAbs)
[24,25]. Importantly, many of these strongly neutralizing hMAbs target quaternary structure
epitopes that form as the envelope glycoprotein is assembled on the virus surface [24–31]. In
addition, we have demonstrated that we can transplant these quaternary epitopes between
DENV serotypes and maintain their biological functions [25,30,32,33]. While determining the
properties of individual hMAbs is valuable, complex polyclonal antibody response governs
protection against subsequent infection. Importantly, the epitope of a single DENV2 serotype-
specific hMAb, 2D22, was shown by our group to be targeted by a large fraction of DENV2
neutralizing antibodies in many, but not all individuals after recovery from DENV2 infections,
highlighting the potential role of this epitope in protective immunity [25]. Despite this, there
are additional DENV2 hMAbs that use other epitopes within E, suggesting that there are
potentially multiple neutralizing antibody epitopes for each serotype. The goals of this study
are to identify novel neutralizing epitopes in DENV2, to develop robust diagnostic reagents
for evaluating epitope specific responses with recombinant DENVs (Fig 1) and to evaluate the
role of these novel and previously described epitopes as targets of polyclonal serum antibodies
induced by natural infections and DENV vaccines.
Fig 1. Sequences of rDENVs. Amino acid sequences of WT and rDENVs used to map antibody epitopes.
https://doi.org/10.1371/journal.ppat.1006934.g001
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Results
Human monoclonal antibodies target quaternary epitopes on DENV2
To characterize the epitopes of DENV2 human monoclonal antibodies (hMAbs), we used a
panel of three DENV2-specific, strongly neutralizing hMAbs (S1 Table). The hMAbs were iso-
lated from two donors infected in geographically distinct locations with different DENV2 geno-
types [34]. The three hMAbs, 3F9, 2D22 and 1L12, bound to whole DENV2 virus (Fig 2A).
Fig 2. DENV2 serotype-specific hMAbs use multiple quaternary epitopes. DENV2 hMAbs 2D22, 1L12 and 3F9 were assessed for their ability to bind whole DENV2
virions (A), DENV2 rE (B), and DENV2 rEDIII (C). Positive control (+) hMAb is DVC10.16, a DENV2 hMAb that uses a simple A-strand epitope contained entirely
within EDIII and 5J7 is a DENV3 serotype-specific hMAb as a negative control (-). (D) Blockade of binding assay where hMAbs 2D22, 1L12 or 3F9 were assessed for
their ability to block 2D22-AP from binding to DENV2.
https://doi.org/10.1371/journal.ppat.1006934.g002
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Recently, it has been reported that human antibodies that strongly neutralize DENVs bind to
quaternary structure epitopes displayed on E homo-dimers or higher order surface structures
required for virion assembly [24,25,29,35]. Consonant with previously published results,
DENV2 hMAb 2D22 did not bind rE or rEDIII, confirming the quaternary epitope specificity
(Fig 2B and 2C). HMAb 1L12 was similar and did not bind to rE or rEDIII (Fig 2B and 2C). In
contrast, hMAb 3F9 weakly bound to rE (Fig 2B). Because hMAb 3F9 bound well to DENV2
virions and weakly to rE, it is likely that the epitope is dependent on E protein assembly into
virions for optimal display. In a blockade of binding assay, 2D22 interfered with 1L12 for bind-
ing to DENV2, suggesting that they recognize proximal or overlapping epitopes on the viral
envelope (Fig 2D). In contrast, 3F9 only partially blocked the binding of 2D22 (Fig 2D) indicat-
ing the two hMAbs recognize distinct epitopes on the viral envelope.
HMAbs 2D22 and 1L12 bind to proximal but distinct epitopes
The cryo-EM structure of hMAb 2D22 Fab in complex with DENV2 has been solved [28] and
the footprint of the antibody spans EDIII and EDII of two E molecules forming each homo-
dimer. Although 2D22 did not bind rEDIII (Fig 2C), the antibody binds and neutralizes a
DENV4 virus containing the entire EDIII from DENV2 (rDENV4/2-EDIII) (Fig 3) [25,28].
Introducing a single point mutation into this virus (rDENV4/2-EDIII R323G), previously
identified as a 2D22 escape mutation [24], (Fig 3A), resulted in a loss of binding and neutrali-
zation (Fig 3B and 3C), confirming 2D22 uses the transplanted EDIII region. HMAb 1L12,
which was isolated from a different donor, showed nearly identical phenotypes, where it
gained binding and neutralization to rDENV4/2-EDIII, indicating that it uses EDIII as part of
its complex quaternary epitope (Fig 3D and 3E). Similarly, the R323G mutation in rDENV4/2-
EDIII results in complete loss of 1L12 binding and neutralization (Fig 3D and 3E).
In addition to binding highly conserved residues in EDII, cryo-EM studies predict that
hMAb 2D22 interacts with eight (307, 309, 310, 316, 318, 362, 363, 364) surface-exposed
amino acids in DENV2 EDIII [28], five (307, 309, 316, 362, 364) of which differ between
DENV2 and DENV4. To refine the map coordinates of 2D22 and 1L12 epitopes, we generated
a new EDIII recombinant virus in which these five amino acids in DENV4 were replaced with
those from DENV2 (rDENV4/2-EDIII 5aa) (Fig 4A). 2D22 was able to partially bind and neu-
tralize this virus at high concentrations of antibody (Fig 4B and 4C). Because the gain in func-
tion is only partial, these data suggest that the epitope requires other critical residues in EDIII
for maximal binding and neutralization. In contrast, hMAb 1L12 did not bind or neutralize
rDENV4 –EDIII 5aa (Fig 4D and 4E), suggesting that its epitope overlaps with 2D22 but
engages a different set of residues on EDIII.
3F9 targets a complex EDI epitope
Competition assays with 2D22 indicated that 3F9 binds to an epitope that has minimal if any
overlap with 2D22 or IL12 (Fig 2D). To map the epitope of hMAb 3F9, we evaluated its bind-
ing to a panel of chimeric recombinant DENVs (rDENVs) with alterations in specific domains
(Fig 5A). Our group has previously shown that strongly-neutralizing hMAbs for DENV1 and
DENV3 use the EDI/II hinge region in their epitope [24,26,27,32]. hMAb 3F9 bound to a
DENV2 virus that had the EDI/II hinge residues replaced with those from DENV4 (rDENV2/
4-EDI/II), suggesting it does not use this region in its epitope (Fig 5B). Conversely, hMAb
3F9 lost most binding to and neutralization of a DENV2 with 11 of its EDI residues replaced
with those from DENV4 (rDENV2/4-EDI), suggesting 3F9 uses an epitope that contains the
replaced residues located in EDI (Fig 5B and 5C). To further characterize the 3F9 epitope, we
tested its binding to and neutralization of a DENV4 virus that contained 22 surface-exposed
Human DENV2 neutralizing antibodies target multiple epitopes
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Fig 3. HMAbs 2D22 and 1L12 use EDIII in their epitopes. (A) rDENV4/2-EDIII is DENV4 virus containing entire EDIII from DENV2. rDENV4/2-EDIII R323G is
rDENV4/2-EDIII virus with single point mutation at residue 323. 2D22 and 1L12 were assessed for their ability to bind (B and D) and neutralize (C and E) recombinant
DENVs in ELISA binding assays and Vero-81 Focus Reduction Neutralization Tests (FRNT). Dotted line in ELISA represents the background signal. FRNT50 represents
the concentration of antibody required to neutralize 50% of infection. # = virus was not neutralized at highest concentration of hMAb tested (5ng/μl).
https://doi.org/10.1371/journal.ppat.1006934.g003
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EDI residues from DENV2 (rDENV4/2-EDI) (Fig 5D). 3F9 bound to and neutralized the EDI
transplant virus, confirming EDI as the main target of this hMAb (Fig 5E and 5F), however
gain of binding was not complete, suggesting there are other residues that are required for
maximal binding. Our data underscore the importance of cryo-EM analyses to help elucidate
the complete 3F9 binding epitope.
In summary, these studies define the location of epitopes recognized by DENV2 type-spe-
cific neutralizing hMAbs 2D22, 1L19 and 3F9. Both 2D22 and 1L19 bind to proximal but dis-
tinct quaternary epitopes centered on EDIII. hMAb 3F9, on the other hand, binds to an
epitope on EDI of the E protein.
DENV2 polyclonal neutralizing antibodies target epitopes defined by
hMAbs
To determine if epitopes defined using hMAbs were targets of polyclonal serum neutralizing
antibodies, we first performed competition (blockade of binding) assays with human immune
sera and hMAbs. Convalescent immune sera from primary DENV2 cases effectively blocked
the binding of 2D22 to its epitope (Fig 6A). Under identical conditions of treatment, DENV1
or DENV3 immune sera did not block 2D22 from binding, confirming that primary DENV2
infection elicited a 2D22-like serotype-specific antibody response (Fig 6A). The same DENV2
immune sera also blocked 3F9 from binding to its epitope, whereas control DENV1 and
DENV3 sera did not (Fig 6B). Remarkably, the ratio of antibodies targeting the two epitopes
appeared to differ across individuals. Two individuals (DT001 and DT158) were more effective
at blocking 2D22 binding than 3F9 binding, whereas DT134 and DT155 were more effective at
blocking 3F9 than 2D22 (Fig 6A and 6B), suggesting these individuals had different ratios of
antibodies targeting each epitope. DENV2 monovalent vaccine sera also blocked 2D22 and
3F9 binding to their respective epitopes (Fig 6C and 6D), indicating that natural infection and
monovalent DENV2 vaccine-elicited antibodies target both these epitopes. Interestingly, no
DENV2 sera samples were able to completely inhibit either 2D22 or 3F9 from binding to their
epitopes, suggesting a limit in the amount these blocking antibodies are present in the sera.
Next, we performed studies to determine if 2D22 and 3F9 epitopes were targets of DENV2
neutralizing serum antibodies. Epitope exchanged recombinant viruses not only provide an
approach to map hMAbs, but they can also be used to quantify epitope-specific neutralizing
antibodies in immune sera. To measure the amount of neutralizing antibodies targeting 2D22
and 3F9 epitopes, we evaluated the ability of polyclonal DENV2 immune sera (10 samples) or
vaccine sera (9 samples) to neutralize rDENV4/2-EDIII (Fig 3A) and rDENV4/2-EDI (Fig 5D)
viruses. Consistent with previous results [25], a large fraction of DENV2 neutralizing antibod-
ies tracked with DENV2 EDIII displayed on the rDENV4/2-EDIII virus (Fig 7A). Interestingly,
most individuals also had neutralizing antibodies that tracked with the DENV2 EDI epitope
displayed on the rDENV4/2-EDI virus (Fig 7A). In some individuals (e.g. DT155) there are
similar levels of neutralizing antibodies that target both epitopes, whereas in other individuals
(e.g. DT128) few if any neutralizing antibodies target the 3F9 EDI epitope (Fig 7A). In individ-
uals that received a monovalent DENV2 vaccine, the majority of their neutralizing antibodies
target EDIII with a much smaller fraction of the response targeting the EDI epitope (Fig 7B).
Overall, there is higher tracking of DENV2 specific responses with both the EDIII and EDI
Fig 4. HMAbs 2D22 and 1L12 use different critical residues in their epitopes. (A) rDENV4/2-EDIII 5aa is a DENV4 virus with five EDIII residues from DENV2.
2D22 and 1L12 were assessed for their ability to bind (B and D) and neutralize (C and E) recombinant DENV in ELISA binding assays and Vero-81 Focus Reduction
Neutralization Tests (FRNT). Dotted line in ELISA represents the background signal, determined as the OD value of wells containing all reagents except for viral
antigen.
https://doi.org/10.1371/journal.ppat.1006934.g004
Human DENV2 neutralizing antibodies target multiple epitopes
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006934 February 26, 2018 8 / 17
Human DENV2 neutralizing antibodies target multiple epitopes
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006934 February 26, 2018 9 / 17
Fig 5. HMAb 3F9 use an epitope contained within EDI. (A) rDENV2/4-EDI/II is DENV2 virus containing EDI/II hinge region residues
from DENV4. rDENV2/4-EDI is DENV2 virus containing EDI residues from DENV4. 3F9 was assessed for its ability to bind (B and E) and
neutralize (C and F) recombinant DENVs in ELISA binding assays and Focus Reduction Neutralization Tests (FRNT) in Vero-81 cells (C) or
C6/36 cells (F). Dotted line in ELISA represents the background signal. (D) rDENV4/2-EDI is DENV4 virus containing EDI residues from
DENV2.
https://doi.org/10.1371/journal.ppat.1006934.g005
Fig 6. DENV2 polyclonal antibodies target EDIII and EDI epitopes. Blockade of binding assay where DENV2 natural infection immune sera (A, B) or DENV2
monovalent vaccine sera (C, D), were assessed for their ability to block 2D22-AP (A, C) or 3F9-AP (B, D) from binding to their respective epitopes on DENV2. DENV
immune sera were depleted of cross-reactive antibodies prior to blockade assay.
https://doi.org/10.1371/journal.ppat.1006934.g006
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epitopes (80% and 54% respectively) in the natural infection sera, as compared with the vac-
cine sera (69% and 30% respectively), suggesting vaccination elicits a slightly different anti-
body response (Table 1).
Discussion
People infected with DENVs develop robust and durable antibody responses that contribute
to protection against re-infection against the homologous serotype; however, rare instances
of re-infection with the same serotype do occur [36]. Antibodies that neutralize DENVs in
cell-culture assays have been considered to be surrogates of protective immunity in vivo. How-
ever, this assumption has been challenged by recent results from DENV vaccine trials. Most
notably, people who received a tetravalent live attenuated DENV vaccine and developed neu-
tralizing antibodies experienced DENV2 breakthrough infections [15]. Breakthrough infections
were also documented with the other serotypes despite the presence of neutralizing antibodies
[15]. This landmark vaccine trial has established that the presence of cell-culture neutralizing
antibodies identified using FRNT assays, is not predictive of protection. Indeed, breakthrough
DENV infections of vaccinated seronegative children underscore the urgency to understand the
essential mechanisms of immune protection in DENV. Moving forward, we need to define key
epitopes on DENVs targeted by neutralizing and potentially protective antibodies and develop
assays to measure both the level and the molecular specificity of neutralizing antibodies.
In this study, we used a panel of hMAbs, human DENV polyclonal immune sera, and
recombinant DENVs (Fig 1) to map the location of epitopes recognized by DENV2 neutraliz-
ing antibodies. First, we used three DENV2 type-specific and strongly neutralizing hMAbs to
map epitopes. hMAbs 2D22 and 1L12 isolated from different people had similar properties
Fig 7. DENV2 polyclonal neutralizing antibodies target two distinct epitopes. DENV2 immune sera (A) and monovalent vaccine sera (B) were evaluated for their
ability to neutralize WT and rDENV in C6/36 Focus Reduction Neutralization Tests (FRNT). Dotted line represents limit of detection (20), samples with no
neutralization were plotted at one half the limit of detection (10). Y-axis indicates sera dilution factor required to neutralize 50% of virus.
https://doi.org/10.1371/journal.ppat.1006934.g007
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and recognized overlapping quaternary epitopes centered on EDIII. Recently Fibriansah et. al.
determined the cryo-EM structure of 2D22 bound to DENV2 and demonstrated that the foot-
print of the 2D22 spanned EDIII and EDII of two E proteins forming a single homo-dimer
[28]. Our data indicating that 2D22 recognizes an EDIII centered quaternary epitope are
entirely consistent with the footprint determined by Fibriansah et. al. We suspect that 1L12
also binds a similar but not identical epitope because of subtle differences in the binding of
2D22 and 1L12 noted in this study. These findings highlight the importance of cryo-EM stud-
ies with IL12, which would provide a more comprehensive view of this larger DENV2 anti-
genic site. Nevertheless, our observation that two individuals infected with different DENV2
genotypes produced type-specific neutralizing hMAbs targeting a similar region suggests that
EDIII is a dominant target of DENV2 neutralizing antibodies. The DENV1, 3 and 4 type-spe-
cific, neutralizing hMAbs identified to date do not map to the regions defined by 2D22 and
1L12 indicating that major targets to type-specific neutralizing Abs can differ between sero-
types. However, several DENV serotype cross-neutralizing hMAbs that bind across the E
homo-dimer have been described recently [29]. While these E dimer-dependent epitope
(EDE) hMAbs partially overlap with the 2D22 epitope, they recognize patches that are highly
conserved between serotypes unlike 2D22.
HMAb 3F9 and 1L12, which were isolated from the same person, have distinct epitopes,
consistent with bivalent recognition of the EDIII and EDI DENV epitopes in most DENV
Table 1. Percent polyclonal neutralization tracking with each epitope.
FRNT50 [Sera Dilution Factor]
α Percent tracking with β
Type Sera ID DENV2 DENV4 rDENV4/2-EDIII rDENV4/2-EDI EDIII EDI
Natural Infection Sera DT001 228 — 431 385 100 100
DT110 2286 97 3170 2004 100 88
DT128 313 — 158 — 51 0
DT134 809 22 550 217 65 24
DT155 208 — 263 320 100 100
DT158 740 — 1030 372 100 50
DT242 410 — 553 175 100 43
ss06/94 153 — 65 43 42 28
ss08/91 107 — 188 70 100 66
ss08/90 154 — 65 62 42 41
Average ±SD 80% ± 27 54% ± 34
DENV2 Monovalent Vaccine Sera 250.10 675 32 267 92 35 9
250.11 783 69 566 62 63 0
250.15 473 79 621 169 100 19
250.05 144 — 232 47 100 33
250.02 144 29 144 36 80 5
250.03 199 — 108 77 55 39
250.07 80 — 58 41 72 52
250.13 743 109 1396 1871 100 100
250.24 348 38 90 83 15 13
Average ±SD 69% ± 30 30% ± 31
α FRNT50 [Sera Dilution Factor] were calculated as the sera dilution factor required to neutralize 50% of the virus, extrapolated from Fig 7.
β Percentage calculated as = (rDENV4/2-EDIII FRNT50 –DENV4 FRNT50)/(DENV2 FRNT50) x 100, and = (rDENV4/2-EDI FRNT50 –DENV4 FRNT50)/(DENV2
FRNT50) x 100.
https://doi.org/10.1371/journal.ppat.1006934.t001
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polyclonal immune sera. The 3F9 epitopes is centered on EDI at a site that overlaps with
known DENV1 and DENV4 neutralizing hMAbs [26,37,38]. Therefore, unlike 2D22, the
region recognized by 3F9 is targeted by type-specific neutralizing antibodies to other serotypes
as well.
Our previous work demonstrated that a majority of the polyclonal antibody response fol-
lowing DENV2 infection and vaccination appeared to be directed to a quaternary EDIII epi-
tope [25]. In some individuals however, neutralization titers did not track as strongly with this
epitope, suggesting that two or more neutralizing epitopes are targeted disproportionately
after primary DENV2 infections. We propose that the EDI epitope defined by the hMAb 3F9
represents a second major neutralizing epitope on DENV2. Most individuals with naturally
acquired DENV2 infections contained antibodies targeting both epitopes however some indi-
viduals targeted only one epitope, or had a skewed response. Similar results were observed in
DENV2 vaccinated individuals, where there were antibodies targeting each epitope, however
the overall response is dominant to the EDIII epitope. Overall, there was a higher response of
antibodies tracking with the EDIII than the EDI epitope in both the natural infection and vac-
cinated sera (Table 1). Interestingly, some individuals had complete neutralizing antibody
responses tracking with both epitopes, suggesting that they potentially generated redundant
populations of antibodies. Generating populations of antibodies directed to different regions
on E could be an important component of an effective antibody response. Viruses can mutate
to escape antibody pressure, but simultaneously escaping antibody pressure to multiple sites
on E would be more challenging [39,40]. As some individuals appear to mount preferential
responses to one site or the other after natural infection or vaccination, it is possible that
strains with natural variation within one of these epitopes may allow for repeat or break-
through DENV2 infections.
Without a clear understanding of what constitutes a protective DENV antibody response to
each serotype, it is challenging to evaluate current DENV vaccines. By defining the epitopes
targeted by DENV2 hMAbs and polyclonal sera, we hope to determine if there are antibody
based correlates of protection and use these to evaluate current vaccines in the pipeline, and
inform the design of next-generation vaccines. Using recombinant DENVs that contain both
gain of function and loss of function epitopes, we can rapidly map in high-throughput assays




Recombinant viruses were constructed using a four-cDNA cloning strategy. The DENV
genome was divided into four fragments, and subcloned into separate cDNA plasmids with
unique type IIS restriction endonuclease cleavage sites at the 5’ and 3’ ends of each fragment.
A T7 promoter was introduced into the 5’ end of the A fragment. Plasmid DNA was grown in
Escherichia coli cells, digested with the corresponding enzymes, gel purified, ligated together
with T4 DNA ligase and transcribed with T7 polymerase to generate infectious genome-length
capped viral RNA transcripts. RNA was electroporated into C6/36 cells, cell culture superna-
tant containing virus was harvested and passaged onto C6/36 cells to generate a passage one
virus stock.
Cells
C6/36 cells (ATCC CRL-1660) were grown in Gibco minimal essential medium (MEM) at
32˚C. Vero-81 cells (ATCC CCL-81) were maintained in Dulbecco’s modified Eagle’s medium
Human DENV2 neutralizing antibodies target multiple epitopes
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(DMEM) at 37˚C. Media were supplemented with fetal bovine serum (FBS) (10% for Vero-81
and 5% for C6/36) which was lowered to 2% after infection. C6/36 media were supplemented
with nonessential amino acids. All media were additionally supplemented with 100U/ml peni-
cillin, 100μg/ml streptomycin and 0.25μg/ml Amphotericin B. All cells were incubated in 5%
CO2.
Ethics statement
Human dengue immune sera used in this study were obtained from a previously described
Dengue Traveler collection at University of North Carolina, and were all primary DENV2 nat-
ural infections [24,25,30]. Vaccine sera were obtained from individuals who received a live-
attenuated monovalent DENV2 vaccine as developed by the US National Institutes of Health
(NIH) and were provided by Anna Durbin and Stephen Whitehead. All human sera samples
were obtained under Institutional Review Board approval and were anonymized.
Virus titration and immunostaining
One day prior to inoculation, 24-well cell culture plates were seeded with 5x104 Vero-81 cells.
Virus stocks were serially diluted 10-fold then added to cells (after growth media was removed)
for one hour at 37˚C. After incubation, cells were overlaid with 1% methylcellulose in Opti-
MEM I (Gibco) supplemented with 2% FBS, nonessential amino acids and 100U/ml penicillin,
100μg/ml streptomycin and 0.25μg/ml Amphotericin B, and incubated at 32˚C. After four
days incubation, overlay was removed, cells were washed with phosphate-buffered saline
(PBS) and fixed in 80% methanol. Cells were blocked in 5% non-fat dried milk (blocking
buffer) then incubated with anti-prM MAb 2H2 and anti-E MAb 4G2 diluted in blocking
buffer. Cells were washed with PBS, then incubated with horseradish peroxidase (HRP)-conju-
gated goat anti-mouse antibody (Sigma) diluted in blocking buffer. Plates were washed and
foci were developed using TrueBlue HRP substrate (KPL).
Binding Enyzme-Linked Immunosorbent Assay (ELISA)
For whole DENV ELISA, plates were coated with 100ng/well mouse MAb 4G2 and 2H2 over-
night at 4˚C. Plates were washed with Tris-buffered saline with 0.05% Tween (TBST) and
blocked in 3% non-fat dried milk in TBST (blocking buffer), and equal quantities of virus (as
previously titrated by ELISA using cross-reactive polyclonal DENV immune sera) were added
and incubated for 1 hour. For rE and rEDIII ELISA, plates were directly coated with protein and
incubated. Plates were washed and primary human MAbs were diluted in blocking buffer and
added to plate for 1 hour. Plates were washed and alkaline phosphate (AP)-conjugated secondary
antibodies were added for 1 hour. Plates were washed, developed using p-nitrophenyl phosphate
substrate and color changes were quantified by spectrophotometry. Assays were developed until
OD values were within linear range of the assay, therefore absolute OD values may vary between
graphs. All binding assays are based on two experiments performed in duplicate.
Blockade of binding assay
Plates were coated with antibody, blocked, and virus was captured as described above. DENV
polyclonal immune sera were depleted of cross-reactive antibodies as described previously
[30]. Briefly, sera were incubated with beads coated with purified DENV4 antigen, then beads
were pelleted to removed cross-reactive antibodies bound to bead:antigen complexes. Cross-
reactive depleted sera were then diluted 1:10 in blocking buffer and incubated for 1 hour.
Plates were washed and alkaline phosphate (AP)-conjugated 2D22 (100ng/well) or 3F9 (50ng/
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well) were added for 1 hour. Plates were developed as described above. Percent blockade was
calculated as follows = (100-[OD of sample/OD of negative control]100). Blockade of binding
assays are based on two experiments performed in duplicate.
Focus reduction neutralization test
For the focus reduction neutralization test (FRNT), hMAbs were diluted 4-fold and mixed
with ~45 focus-forming units (FFU) of virus, and incubated for 1 hour at 37˚C. After incuba-
tion, virus:hMAb mixture was added to Vero-81 cells for 1 hour at 37˚C or C6/36 cells for 1
hour at 32˚C, then overlay was added and cells were incubated and fixed and stained as
described above. Foci were counted and FRNT50 titers were calculated as the concentration of
antibody or sera dilution factor required to neutralize 50% of the virus. Neutralization assays
are based on two (HMAbs) or one (immune sera) experiments performed in triplicate.
Supporting information
S1 Table. DENV2 monoclonal antibodies. Virus was isolated from subject DT001, sequenced
and found to be part of the cosmopolitan genotype [41]. Subject IRB019 was infected in Thai-
land in 1997 when the DENV2 Asian genotype strain was circulating in the region.
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